Stockscreener 앱 받기
12.80
3.54%
-0.47
시간 외 거래:
12.81
0.010
+0.08%
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
WAVE Life Sciences (NASDAQ:WVE) Given New $27.00 Price Target at Wells Fargo & Company - MarketBeat
WVE Stock Update: Wells Fargo Adjusts Price Target Amidst Steady Ratings | WVE Stock News - GuruFocus
Paul Bolno Sells 10,480 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock - MarketBeat
Kyle Moran Sells 3,588 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
(02/11/26) Top Picks 2026: Wave Life Sciences Ltd. (WVE) - moneyshow.com
Published on: 2026-02-10 01:59:11 - baoquankhu1.vn
Wave Life Sciences (WVE) regains rights to potential rare genetic disorder treatment - MSN
The Bull Case For Wave Life Sciences (WVE) Could Change Following WVE-006 Rights Reversion And FDA Talks - Yahoo Finance
Assessing Wave Life Sciences (WVE) Valuation After A 7x Three Year Total Return - Yahoo Finance
Why The Wave Life Sciences WVE Story Is Shifting After New RNA And AATD Updates - Yahoo Finance
Will Regaining Full Rights to WVE-006 and Pursuing FDA Fast Track Change Wave Life Sciences' (WVE) Narrative - simplywall.st
How (WVE) Movements Inform Risk Allocation Models - Stock Traders Daily
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment - Finviz
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Wave Life Sciences receives back rights to AATD therapy from GSK - MSN
13 Best Revenue Growth Stocks to Buy Right Now - Insider Monkey
WAVE Life Sciences (NASDAQ:WVE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
WAVE Life Sciences (NASDAQ:WVE) Now Covered by Bank of America - MarketBeat
WVE Sees Analyst Rating Boost with Raised Price Target | WVE Stock News - GuruFocus
Assessing Wave Life Sciences (WVE) Valuation After Regaining Global Rights To WVE-006 From GSK - Sahm
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Wave Life Sciences (WVE) and Arcellx Inc (ACLX) - The Globe and Mail
Wave Life Sciences Ltd. (WVE): Analyst Consensus Highlights 143.73% Potential Upside for Biotech Innovator - DirectorsTalk Interviews
Wave Life Sciences price target raised to $50 from $47 at Clear Street - Yahoo Finance
WVE Sees Price Target Boost: Canaccord Genuity Adjusts to $43.00 - GuruFocus
Wave Life Sciences Regains Full Rights to WVE-006 from GSK - intellectia.ai
WAVE Life Sciences stock price target raised to $43 from $40 at Canaccord - Investing.com Australia
WAVE Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
Wave Life Sciences regains rights to AATD therapy WVE-006 from GSK - Investing.com Nigeria
Wave Life Sciences regains rights to AATD therapy WVE-006 from GSK By Investing.com - Investing.com South Africa
WAVE Life Sciences stock rating reiterated by Raymond James on regained drug rights - Investing.com Australia
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
Clear Street raises WAVE Life Sciences stock price target to $50 on AATD program - Investing.com Nigeria
Wave Life Sciences stock rises after regaining full rights to AATD therapy By Investing.com - Investing.com South Africa
Wave Life Sciences stock rises after regaining full rights to AATD therapy - Investing.com India
Wave Life Sciences (WVE) Reclaims Rights to AATD Asset WVE-006 - GuruFocus
Wave Life Sciences plans to accelerate regulatory engagement with full control of WVE-006 - marketscreener.com
Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path - TipRanks
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Wave Life Sciences Ltd Accelerates Regulatory Engagement for WVE-006 - TradingView
Wave RNA drug for rare lung and liver disease heads for FDA talks - Stock Titan
How Investors May Respond To Wave Life Sciences (WVE) Expanding PRISM RNA Platform Via Big-Pharma Partnerships - Sahm
Market Outlook: Does CBTJ stock reflect fundamentalsJuly 2025 Volume & High Accuracy Investment Entry Signals - baoquankhu1.vn
Federated Hermes Inc. Has $27.46 Million Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
WAVE Life Sciences (NASDAQ:WVE) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Wave Life Sciences Ltd. (WVE) Growth Potential: Analysts Predict 141% Upside - DirectorsTalk Interviews
Trading Systems Reacting to (WVE) Volatility - Stock Traders Daily
Aug Outlook: Will Standard BioTools Inc stock recover after earningsPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Buyback Watch: Will Wave Life Sciences Ltd outperform small cap indexes2025 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
Moving Averages: Is Wave Life Sciences Ltd stock suitable for long term investingWeekly Stock Report & Advanced Technical Signal Analysis - baoquankhu1.vn
Emerald Mutual Fund Advisers Trust Sells 171,427 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat
Volatility Watch: Can Wave Life Sciences Ltd beat the S P 500Dollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
WAVE Life Sciences Ltd. $WVE Shares Sold by Emerald Advisers LLC - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
US Stocks Recap: Will Wave Life Sciences Ltd. outperform small cap indexes2025 AllTime Highs & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Leader with 133.86% Potential Upside - DirectorsTalk Interviews
1.24%
0.19%
자본화:
|
볼륨(24시간):